Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Lexicon Pharmaceuticals Third Quarter 2024 Results Conference Call. All participants will be in a listen-only mode.
Posts Tagged ‘NASDAQ:LXRX’
10 Best Multibagger Penny Stocks of 2025
The term "multibagger" was coined by Peter Lynch in his book titled "One Up On Wall Street" to describe those stocks whose share prices increase several times more than an investor...
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q2 2024 Earnings Call Transcript
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q2 2024 Earnings Call Transcript August 1, 2024Lexicon Pharmaceuticals, Inc. beats earnings expectations.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2024 Earnings Call Transcript
Operator: Good day, everyone, and welcome to the Lexicon Pharmaceuticals First Quarter 2024 Financial Results Conference Call.
15 Hot Penny Stocks On the Move
Strong inflation data from January and the Fed's indications that it would take its time before initiating rate cuts threw cold water on investors' hopes of getting rid of uncertainties...
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2023 Earnings Call Transcript
Operator: Good day and welcome to the Lexicon Pharmaceuticals' Third Quarter 2023 Financial Results Conference Call. Today all participants will be in a listen-only mode.
15 Best Affordable Stocks To Buy Under $5
In this article, we discuss 15 best affordable stocks to buy under $5.
10 Healthcare Stocks with Insider Buying
Investors were processing inflation report on August 10 to find clues on the Federal Reserve’s possible moves. CPI’s growth in July was identical to that of June’s.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q2 2023 Earnings Call Transcript
Operator: Good day, and welcome to the Lexicon Pharmaceuticals Second Quarter 2023 Financial Results Conference Call. All participants will be in listen-only mode.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2023 Earnings Call Transcript
Operator: Good day everyone, and welcome to the Lexicon Pharmaceuticals First Quarter 2023 Financial Results Conference Call. All participants will be in a listen-only mode.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2022 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Lexicon Pharmaceuticals Fourth Quarter 2022 Earnings Conference Call. All participants will be in a listen-only mode.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2022 Earnings Call Transcript
Operator: Good day, ladies and gentlemen. Welcome to the Lexicon Pharmaceuticals Inc. Third Quarter 2022 Earnings Conference Call.
Hedge Fund and Insider Trading News: Steve Cohen, Ken Griffin, Andrew Law, Marcho Partners, Elliott Management, Balyasny Asset Management, Chipotle Mexican Grill, Inc. (CMG), Lexicon Pharmaceuticals, Inc. (LXRX), and More
A Conservative donor who has given more than £3 million to the party has become the latest senior businessman to back Liz Truss.
Hedge Fund and Insider Trading News: Coatue Management, Lone Pine Capital, Apollo Global Management, Heptagon Capital, SEB Investment Management, Zoom Video Communications Inc (ZM), Repare Therapeutics Inc (RPTX), and More
Pine Labs has raised $75-$100 million led by US-based billionaire Stephen Mandel's hedge fund Lone Pine Capital, valuing the Noida-based merchant-commerce startup at more than...
Should You Buy Lexicon Pharmaceuticals, Inc. (LXRX)?
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.
Were Hedge Funds Right About Betting On Lexicon Pharmaceuticals, Inc. (LXRX)?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November.
Is Lexicon Pharmaceuticals, Inc. (LXRX) Going to Burn These Hedge Funds?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th.
Here is What Hedge Funds Think About Lexicon Pharmaceuticals, Inc. (LXRX)
Is Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research.
Here’s What Hedge Funds Think About Lexicon Pharmaceuticals, Inc. (LXRX)
The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources...
Hedge Fund and Insider Trading News: Bill Ackman, Jana Partners, BlueCrest Capital Management, Iqvia Holdings Inc (IQV), Twelve Seas Investment Company (TWLVU), ABIOMED, Inc. (ABMD), and More
Billionaire hedge fund manager William Ackman, whose investment assets have shrunk by more than half in the last three years, has made a second round of staff cuts and laid off...
Hedge Fund and Insider Trading News: Paul Tudor Jones, Rob Citrone, Facebook, Inc. (FB), Christopher & Banks Co. (CBK), Lexicon Pharmaceuticals, Inc. (LXRX), and More
The 50-year-old definition of capitalism in the U.S.
Here’s What’s Next For Lexicon Pharmaceuticals, Inc. (LXRX) And Dynavax Technologies Corporation (DVAX)
Two companies have logged strong starts to the week in the biotech space so far, and both are moving on FDA driven catalysts.
Biotech Movers And Shakers: Lexicon Pharmaceuticals, Inc. (LXRX) And Neuroderm Ltd (NDRM)
Right then, it’s time to take a look at who moved during the start of this week, and what’s driving the action in the biotech sector.
Lexicon Pharmaceuticals, Inc. (LXRX): Are Hedge Funds Right About This Stock?
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset...
Two Biotechs With Bad News This Week: What Happens Now?
When things go well in biotech, it can be a great ride.
Delving Into The Lexicon Pharmaceuticals, Inc. (LXRX) Data
Lexicon Pharmaceuticals, Inc.
Do Investors Like Lexicon Pharmaceuticals, Inc. (LXRX) or Ariad Pharmaceuticals, Inc. (ARIA) More?
It is already common knowledge that individual investors do not usually have the necessary resources and ability to properly research an investment opportunity.
These Biotech Stocks Move in Opposing Directions Today and Hedge Funds Say You Should Bet on One of Them
Shares of Heron Therapeutics Inc (NASDAQ:HRTX) are up by more than 20% in early trading, following positive Phase 2 reports on HTX-011, an anesthetic and anti-inflammatory ...
Lexicon Pharmaceuticals, Inc. (LXRX) Flies On Cancer Drug Study Results; Hedge Funds Saw This Coming
Shares of Lexicon Pharmaceuticals, Inc.
Nektar Therapeutics (NKTR): Insiders Aren’t Crazy About It But Hedge Funds Love It
Now, according to many of your peers, hedge funds are assumed to be useless, outdated investment vehicles of a forgotten age.
Acorda Therapeutics Inc (ACOR): Insiders Aren’t Crazy About It But Hedge Funds Love It
To many investors, hedge funds are assumed to be bloated, outdated investment tools of a forgotten age.
PDL BioPharma Inc. (PDLI): Hedge Fund and Insider Sentiment Unchanged, What Should You Do?
In the eyes of many market players, hedge funds are seen as overrated, old investment tools of a period lost to current times.
Santarus, Inc. (SNTS): Hedge Funds Are Bullish and Insiders Are Undecided, What Should You Do?
In the financial world, there are a multitude of gauges investors can use to watch publicly traded companies. A couple of the best are hedge fund and insider trading interest.
Hedge Funds Are Selling Sarepta Therapeutics Inc (SRPT)
If you were to ask many of your fellow readers, hedge funds are seen as overrated, old investment vehicles of a period lost to current times.
Lexicon Pharmaceuticals, Inc. (LXRX), Pfizer Inc. (PFE), GlaxoSmithKline plc (ADR) (GSK): Why Clinical Trials Fail
Drugs fail their clinical trials for all kinds of reasons. Sometimes, it's related to efficacy; sometimes, it's safety related.
What Hedge Funds Think About VIVUS, Inc. (VVUS)
In the 21st century investor’s toolkit, there are dozens of metrics investors can use to track Mr. Market.
Lexicon Pharmaceuticals, Inc. (LXRX), Merck & Co., Inc. (MRK): The Worst-Performing Biotech Stocks of the Last Decade
Suppose we filled a jar with slips of paper with the names of biotech companies that have been around for at least 10 years and with a market cap of at $500 million or more written...
Lexicon Pharmaceuticals, Inc. (LXRX): Insiders Aren’t Crazy About It
In the 21st century investor’s toolkit, there are a multitude of metrics investors can use to monitor stocks. A duo of the best are hedge fund and insider trading activity.
Is Nektar Therapeutics (NKTR) Going to Burn These Hedge Funds?
Nektar Therapeutics (NASDAQ:NKTR) was in 8 hedge funds' portfolio at the end of March.
Amarin Corporation plc (ADR) (AMRN), Lexicon Pharmaceuticals, Inc. (LXRX): Which of These Billion-Dollar Biotechs Is a Buy?
It has been a rough year for Amarin Corporation plc (ADR) (NASDAQ:AMRN) and its long-term investors.
Santarus, Inc. (SNTS): Insiders Are Buying, Should You?
If you'd ask most shareholders, hedge funds are assumed to be underperforming, old investment tools of the past.
This Metric Says You Are Smart to Buy Sarepta Therapeutics Inc (SRPT)
Sarepta Therapeutics Inc (NASDAQ:SRPT) was in 19 hedge funds' portfolio at the end of March.
Acorda Therapeutics Inc (ACOR): Insiders Are Dumping, Should You?
Acorda Therapeutics Inc (NASDAQ:ACOR) was in 10 hedge funds' portfolio at the end of the fourth quarter of 2012.
Pacific Biosciences of California (PACB), Lexicon Pharmaceuticals, Inc. (LXRX): 3 Stocks With Insider Interest
The global economy is still going through the initial stages of recovery and waiting on positive news from European markets.
